Caplacizumab is a von Willebrand factor (vWF)-mediated antibody used for treating acquired thrombotic thrombocytopenic purpura (aTTP).
vWF is a factor required for blood clotting.
aTTP is a blood disorder with low platelet count, areas of bleeding under the skin (purpura), low red blood cell count, and anemia.
Caplacizumab is prescribed for treating acquired thrombotic thrombocytopenic purpura (aTTP)
Previous severe allergic reaction to caplacizumab-yhdp.
Caplacizumab should be administered upon the initiation of plasma exchange therapy.
The first dose should be given by a healthcare provider as a bolus( at a time) intravenous injection.
The recommended dose is as follows:
1st day: 11 mg bolus intravenous( into the vein) injection 15 minutes before plasma exchange followed by 11 mg subcutaneous injection (into the fat layer of skin) after completion of plasma exchange on day 1.
Subcutaneous injection in the abdomen once daily for 30 days after plasma exchange.
If a dose of Caplacizumab is missed during the plasma exchange, it should be given as soon as possible. If a dose is missed after the plasma exchange, it should be given within 12 hours of the scheduled time of administration. After 12 hours, the missed dose should be skipped and the next daily dose should be given according to the usual dosing schedule.
Caplacizumab is given by injection -into the vein or into the fat layer of skin by a health care provider.
• Caplacizumab increases the risk of bleeding like epistaxis(nasal bleeding), gingival(gum) bleeding, gastrointestinal bleeding etc especially among patients with diseases like hemophilia and other clotting factor deficiencies.
• Stop caplacizumab for 7 days before any planned surgery, dental procedures or other invasive interventions. If emergency surgery is required, the use of von Willebrand factor concentrate should be considered.
Side effects include:
• Gastrointestinal : Gum bleeding, rectal hemorrhage, abdominal wall hematoma
• General: Fatigue (tiredness), fever, bleeding and itching at injection site, catheter site hemorrhage
• Musculoskeletal: Back pain, muscle pain
• Nervous system :Headache,
• Renal:-Urinary tract infection ,Blood in urine
• Reproductive system :Vaginal hemorrhage ,Menorrhagia(excess bleeding during mensus)
• Respiratory: Epistaxis ,Dyspnea(difficulty breathing)
• Skin: Urticaria (generalized skin reaction)
Caplacizumab may increase bleeding risk in the fetus and neonate. Pregnant women receiving caplacizumab should be carefully monitored for evidence of excessive bleeding.
Usage of caplacizumab with other anticoagulants increase bleeding risks.
Store caplacizumab in refrigerator 2°C to 8°C. Do not freeze and protect from light. Unopened vial of caplacizumab can be stored in the original carton at room temperature up to 2 months.